



SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors

September 12, 2023 at 9:00 AM EDT

SomaLogic's SomaScan® platform was used to target 15 markers shared among all cancer types.

BOULDER, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE) -- In a [new paper published in Nature's Scientific Reports](#), researchers at SomaLogic Inc. studied the value of protein biomarkers in the early detection of cancer and the stratification of cancerous tumors. The research team identified 15 blood proteins shared among all cancer types as well as models to stratify tumor types. The goal of this research was to identify protein biomarkers that could be used to detect early-stage cancer during regular screenings, which could increase treatment options for patients, minimize the likelihood of chemotherapy resistance and reduce the risk of tumor metastases.

Early detection of cancer offers the best chance of successful treatment, but many cancers are only diagnosed at an advanced stage after patients exhibit symptoms or the disease is found during an unrelated procedure. Currently, screening tests for breast, colon, cervical, prostate and lung cancer are limited by their lack of sensitivity, invasiveness, high false positives and low patient compliance. Using the SomaScan® platform and machine learning, researchers at SomaLogic sought to overcome these challenges and limitations by exploring the possibility of identifying tumor-associated proteins in a mouse model that can be detected with a simple blood test early in the disease process and use them to establish the presence and identity of cancerous tumors.

"In addition to tumor-specific biomarker models, we were also able to identify sentinel proteins in plasma for four different tumor types," said SomaLogic Chief Science Officer Nebojsa Janjic, who was an author on the paper. "Using our proteomics technology, we also developed a pan-cancer prediction model that can detect the presence of ovarian, colon and breast cancer tumors as small as 0.15 inches (<0.75mm³) by measuring circulating proteins in a small blood sample."

Since lung cancer is the leading cause of mortality from cancer, the team focused on two human non-small cell lung cancer cell lines. They then expanded their research to include breast, colon, and ovarian cancer cell lines. Protein patterns allowed the researchers to identify biomarkers unique for each tumor type, as well as shared biomarkers that can detect the presence and predict the volume of these tumors.

For more than twenty years, SomaLogic has grown from its roots in the research lab to become a global leader in proteomics with technology that delivers the quality and quantity of biological insights life science researchers need - from lab to last mile.

About SomaLogic

SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body. For more than 20 years we've supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at www.somalogic.com and follow [@somalogic](https://www.linkedin.com/company/somalogic) on LinkedIn.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "forecast," "guidance," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "continue," "will likely result," "possible," "potential," "predict," "pursue," "target" and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic's control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – "Risk Factors" in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

SomaLogic Media Contact

Emilia Costales

720-798-5054

ecostales@somalogic.com

SomaLogic Investor Contact

Marissa Bych
Gilmartin Group LLC
investors@somalogic.com